LENZ (LENZ Therapeutics) Total Liabilities: $26.04 Mil (As of Mar. 2026)


LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.89
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics Total Liabilities?

LENZ Therapeutics LENZ +1.73% 12 Total Liabilities is $26.04 Mil as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

LENZ Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $26.04 Mil.

LENZ Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($16.78 Mil) to Dec. 2025 ($21.54 Mil) and increased from Dec. 2025 ($21.54 Mil) to Mar. 2026 ($26.04 Mil).

LENZ Therapeutics's annual Total Liabilities declined from Dec. 2023 ($163.09 Mil) to Dec. 2024 ($11.22 Mil) but then increased from Dec. 2024 ($11.22 Mil) to Dec. 2025 ($21.54 Mil).

LENZ Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics Total Liabilities Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
32.55 71.12 163.09 11.22 21.54

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.24 10.97 16.78 21.54 26.04
LENZ
12GF Score
LENZ Therapeutics Inc LENZ
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

LENZ Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.187+(0.35+-2.1094237467878E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=21.54

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=305.876-284.339
=21.54

LENZ Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=25.806+(0.237+-1.6653345369377E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=26.04

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=272.535-246.492
=26.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $26.04 Mil mean?
LENZ Therapeutics (LENZ) has a Total Liabilities of $26.04 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LENZ Therapeutics and its competitors.
Is LENZ Therapeutics' Total Liabilities too high?
LENZ Therapeutics' current Total Liabilities is $26.04 Mil. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Total Liabilities compare to KRRO and ANTX?
LENZ Therapeutics' Total Liabilities of $26.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LENZ Therapeutics and its competitors. LENZ Therapeutics's current Total Liabilities is $26.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Total Liabilities of $26.04 Mil. The current Total Liabilities is $26.04 Mil. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Total Liabilities is $26.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.89
Price